Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
Joint PSI Pharmaceutical Statistics & DIA Statistics Community
DIA Chair: Tad Archambault, Principal, Virtu Stat, Ltd.
Speaker: Daniel Wachtlin, Interdisciplinary Centre for Clinical Trials (IZKS), University Medical Centre Mainz
Blinded Sample Size Recalculation in Longitudinal Clinical Trials Using Generalized Estimating Equations
Daniel Wachtlin and Meinhard Kieser
Therapeutic Innovation & Regulatory Science, Vol. 47, Issue 4, pp. 460-467, 2013 Abstract | Paper+ | Slides
PSI Chair: Byron Jones, NOVARTIS
Speaker: Andrew Hartley, PPD
Adaptive blinded sample size adjustment for comparing two normal means—a mostly Bayesian approach
Andrew M. Hartley
Pharmaceutical Statistics, Vol. 11, Issue 3, pp. 230-240, 2012 Abstract | Paper+ | Slides
Discussant: Peiling Yang, Statistical Team Leader, Division of Biometrics I, US FDA Slides
+ Papers available to view from October 22nd 2013 to November 5th 2013.
For a flier advertising the event, please click here.
PSI Introduction to Industry Training (ITIT) Course - 2025/2026
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
PSI Webinar: Methodology and first results of the iRISE (improving Reproducibility In SciencE) consortium
This 1-hour webinar will be an opportunity to hear about the methodology and first results of the iRISE consortium. iRISE is working towards a better understanding of reproducibility and the interventions that work to improve it. At the end of the presentation there will also be the opportunity to ask questions.
One-day Event: Change Management for Moving to R/Open-Source
This one-day event focuses on the comprehensive management of transitioning to R/Open-Source, addressing the challenges and providing actionable insights. Attendees will participate in sessions covering essential topics such as training best practices, creating strategic plans, making the case to senior management, and managing both statistical and programming aspects of the transition.
PSI Book Club - The Art of Explanation: How to Communicate with Clarity and Confidence
Develop your non-technical skills by reading The Art of Explanation by Ros Atkins and joining the Sept-Dec 2025 book club. You will be invited to join facilitated discussions of the concepts and ideas and apply skills from the book in-between sessions.
This course is aimed at biostatisticians with no or some pediatric drug development experience who are interested to further their understanding. We will give you an introduction to the pediatric drug development landscape. This will include identifying the key regulations and processes governing pediatric development, a discussion on the needs and challenges when conducting pediatric research and a focus on the ways to overcome these challenges from a statistical perspective.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
EFSPI/PSI Causal Inference SIG Webinar: Instrumental Variable Methods
The webinar is targeted at statisticians working in the pharmaceutical industry, and the objective is to 1) provide a basic understanding of IV methodology including how it relates to causal inference, and 2) present two inspirational pharma-relevant applications.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This is an exciting, new opportunity for an experienced Statistician looking to take the next step in their career. Offered as a remote or hybrid position aligned with our site in Harrogate, North Yorkshire.